Adipotide
Also known as: Prohibitin-TP01, CKGGRAKDC-GG-D(KLAKLAK)2
Prohibitin-Targeting Peptidomimetic | Experimental Anti-Obesity
Overview
Chimeric adipose-vasculature-targeted peptidomimetic targeting prohibitin/annexin A2 on white adipose tissue endothelium, delivering pro-apoptotic D-(KLAKLAK)2 motif. In obese primates it produced rapid fat loss with improved insulin resistance, yet development halted after Phase 1 due to kidney safety signals.
Key benefits
- Rapid fat-mass reduction via selective white adipose tissue vascular targeting
- Improved insulin sensitivity following adipose reduction
- Non-CNS peripheral mechanism distinct from appetite suppressants
Mechanism of action
CKGGRAKDC ligand homes to prohibitin/annexin A2 on white-fat endothelium; linked D-(KLAKLAK)2 disrupts mitochondrial membranes post-internalization, triggering localized endothelial apoptosis and adipocyte loss.
Molecular data
- Type
- Chimeric peptidomimetic
- Half-life
- Not established
Sequence
CKGGRAKDC-GG-D(KLAKLAK)2
Indications
What the research community uses this compound for, with self-reported effectiveness.
Weight Loss
Adipose Mass Reduction
Most effectiveSelective white adipose tissue vascular targeting produced 7-15% body-weight loss over 4 weeks in obese macaques.
Metabolic
Insulin Resistance
EffectiveImproved insulin response (reduced insulin AUC) following fat-mass reduction in primates.
Appetite Control
Non-CNS Mechanism
ModerateWeight loss without primary appetite suppression; peripheral vascular approach.
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Injectable
Rapid fat-mass reduction in obese non-human primates with improved insulin sensitivity; direct white adipose tissue vascular targeting.
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| Primate Research Replication | 0.43 mg/kg | Once daily | SubQ |
| Dose-Finding (Research) | 0.10-0.75 mg/kg | Once daily (escalating tiers) | SubQ |
Preparation
You will need
- Lyophilized peptide vial
- Bacteriostatic water (BAC water)
- Alcohol swabs & sterile syringes
- Insulin syringes (0.5-1 mL)
Steps
- Sanitize hands and workspace; swab vial septum
- Inject BAC water slowly down vial wall; do not jet onto powder
- Gently swirl until fully dissolved (do not shake)
- Label with concentration/date; store at 2-8°C
Work out the water volume and syringe units in the reconstitution calculator →
Interactions
Pairwise interactions with other compounds you might be cycling — the same data behind the cycle builder's safety check.
Nephrotoxic Drugs
AvoidAdipotide shows dose-dependent proximal tubule injury; avoid additional renal insults.
Semaglutide
MonitorPotential additive dehydration/GI effects; monitor renal function.
Tirzepatide
MonitorOverlapping weight-loss effects; monitor kidney function, volume status, electrolytes.
Cagrilintide
MonitorNo clinical data on co-administration; mechanisms differ.
AOD-9604
MonitorNo published data on combined use or pharmacodynamic interaction.
CJC-1295/Ipamorelin
MonitorMetabolic effects may confound body-composition endpoints.
Melanotan II
MonitorTheoretical vascular/pressor effects; stagger dosing, monitor BP and hydration.
BPC-157
CompatibleNo known direct interaction; distinct mechanisms and targets.
Timeline
Typical week-by-week effects reported in clinical and observational data.
- Week 1-2
Early reduction in abdominal circumference
- Week 2-4
Progressive weight/fat-mass decline
- Post-Discontinuation
Partial rebound possible; lab signals include mild creatinine rise and electrolyte shifts
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Mild creatinine elevation
- Electrolyte shifts
- Dose-dependent proximal tubule changes (reversible in primates)
Stop signs — stop and seek advice
- Sustained creatinine elevation or oliguria
- Progressive electrolyte abnormalities
- Severe injection-site reactions or systemic symptoms
- Unexpected toxicity
Contraindications
- Pregnancy/lactation (not studied)
- Dehydration
- Concurrent nephrotoxic medications
Monitoring
- Serum creatinine weekly
- Blood urea nitrogen (BUN) weekly
- Urinalysis weekly
- Electrolytes weekly
Quality checks
What a legitimate product looks like, what should give pause, and what should make you stop.
Good signs
- Intact lyophilized cake - white, uniform indicates proper lyophilization
- Clear solution - fully dissolved, particle-free after reconstitution
Warning signs
- Minor clumping may form from shipping; should dissolve with gentle swirl
Stop signs — don't use
- Collapsed/moist cake suggests temperature excursion; do not use without QC
- Cloudiness/precipitate indicates degradation or contamination—discard
References
Primary literature and clinical-trial data informing this entry.
A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys
2011
Rhesus macaques at 0.43 mg/kg SC daily for 28 days showed 7.4-14.7% weight loss; insulin resistance improved; mild, dose-dependent, reversible proximal tubule changes.
Reversal of obesity by targeted ablation of adipose tissue
2004
Mice with diet-induced obesity showed ~30% weight reduction; adipose vascular apoptosis; metabolic normalization.
Prohibitin/Annexin A2 Interaction Regulates Fatty-Acid Transport
2016
Mechanistic validation of prohibitin/ANXA2 axis in adipose tissue, core to TP01 targeting.
Mixed-Chirality Prohibitin Peptide: D-(RLARLAR)2 Enhances Stability
2025
Next-generation prohibitin constructs improve serum stability and efficacy vs. first-generation TP01.
Last updated . How this page was sourced is described in the methodology.